Reaction

Demyelination reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,067 reports · 103 co-occurring drugs

As of the last recalculation, Demyelination appears in 4,067 FAERS reports alongside 103 co-occurring drug terms. The strongest observed disproportionality signal is DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED (PRR 24.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Diphenhydramine Hydrochloride Capsule, Liquid Filled	98	24.0	24.1
Adalimumab-Aaty	181	20.4	20.5
Adalimumab-Fkjp	177	20.4	20.5
Adalimumab-Adaz	191	19.4	19.5
Ocrelizumab	211	18.3	18.4
Cetirizine Hydrochloride Allergy	103	17.8	17.9
Cetirizine Hydrochloride Tablets	103	17.8	17.9
Esomeprazole Magnesium Capsule, Delayed Release	46	16.4	16.4
Esomeprazole Magnesium Delayed Release Capsules	46	16.4	16.4
Esomeprazole Magnesium Dihydrate	46	16.3	16.4
Azathioprine	257	15.9	15.9
Methylprednisolone Acetate	22	14.1	14.2
Anakinra	39	12.1	12.2
Vitamin E	73	12.1	12.1
Leflunomide	231	11.9	11.9
Tocilizumab	249	11.8	11.9
Infliximab	448	11.7	11.7
Rituximab	375	9.9	9.9
Fingolimod Hcl	148	9.1	9.1
Abatacept	227	8.8	8.8
Glatiramer Acetate	100	8.8	8.8
Cetirizine	124	8.4	8.4
Gentamicin	21	8.3	8.3
Methylprednisolone	209	8.1	8.1
Cefuroxime	18	8.1	8.1
Etanercept	743	7.5	7.6
Gentamicin Sulfate	23	7.5	7.5
Cyclosporine	155	7.4	7.4
Methotrexate	531	7.3	7.3
Sulfasalazine	105	7.0	7.0
Dextrose	18	7.0	7.0
Methotrexate Sodium	578	6.9	6.9
Dextrose Monohydrate	18	6.9	6.9
Atenolol	157	6.2	6.2
Interferon Beta-1B	23	6.2	6.2
Imatinib	21	6.1	6.1
Esomeprazole	73	6.1	6.1
Piperacillin And Tazobactam	15	6.0	6.0
Adalimumab	696	5.9	5.9
Cetiirizine	48	5.9	5.9
Ofatumumab	36	5.6	5.6
Alemtuzumab	21	5.6	5.6
Methylprednisolone Sodium Succinate	48	5.3	5.3
Duloxetine	71	5.3	5.3
Piperacillin Sodium And Tazobactam Sodium	20	5.2	5.2
Hydroxychloroquine Sulfate	90	5.1	5.2
Diphenhydramine Hydrochloride	158	5.0	5.0
Lansoprazole	169	5.0	5.0
Baclofen	83	5.0	5.0
Dornase Alfa	19	5.0	5.0
Fludarabine Phosphate	37	4.9	4.9
Mercaptopurine	16	4.7	4.7
Piperacillin Sodium,Tazobactam Sodium	24	4.7	4.7
Modafinil	29	4.6	4.6
Duloxetine Hydrochloride	161	4.5	4.5
Hyoscyamine Sulfate	8	4.5	4.5
Meperidine Hydrochloride	8	4.5	4.5
Meloxicam	50	4.4	4.5
Minocycline	10	4.4	4.4
Cetirizine Hydrochloride	137	4.4	4.4
Golimumab	69	4.2	4.2
Tapentadol Hydrochloride	27	4.1	4.2
Isoniazid	13	4.1	4.1
Teriflunomide	34	3.9	3.9
Meropenem	24	3.8	3.8
Diphenhydramine	46	3.8	3.8
Thiotepa	7	3.8	3.8
Dalfampridine	52	3.7	3.7
Busulfan	11	3.6	3.6
Mesalamine	39	3.6	3.6
Tofacitinib Citrate	9	3.5	3.5
Siponimod	6	3.4	3.4
Tofacitinib	121	3.4	3.4
Gefitinib	6	3.4	3.4
Aripiprazole Oral	27	3.4	3.4
Aripiprazole Orally Disintegrating	27	3.4	3.4
Rifampin	9	3.2	3.2
Ustekinumab	62	3.1	3.1
Propofol	22	3.1	3.1
Amantadine	9	3.0	3.0
Interferon Beta-1A	105	2.8	2.8
Natalizumab	95	2.7	2.7
Erlotinib	5	2.6	2.6
Entecavir	6	2.6	2.6
Loratadine Tablet	27	2.6	2.6
Ado-Trastuzumab Emtansine	4	2.4	2.4
Canakinumab	5	2.4	2.4
Peginterferon Beta-1A	6	2.3	2.3
Diroximel Fumarate	5	2.1	2.1
Polatuzumab Vedotin	4	2.1	2.1
Erlotinib Hydrochloride	5	2.0	2.0
Irinotecan Hydrochloride	5	2.0	2.0
Ravulizumab	5	1.9	1.9
Ozanimod Hydrochloride	3	1.8	1.8
Ipilimumab	15	1.8	1.8
Osimertinib	11	1.8	1.8
Temozolomide	7	1.7	1.7
Cortisone Acetate	4	1.7	1.7
Rimegepant Sulfate	4	1.6	1.6
Dimethyl Fumarate	38	1.6	1.6
Remdesivir	4	1.5	1.5
Certolizumab Pegol	33	1.4	1.4
Guselkumab	7	1.0	1.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.